Date:	--/--/-- --:--:--
Event Id:	E5L5V436T
Action Type:	ACQUISITION
Action Status:	ANNOUNCED
Acquirer Symbol:
Target Symbol:	CRNX
Updated:	--/--/-- --:--:--
Purchase Price Per Share:	85
Price Per Share Currency:	USD
News References:	https://www.businesswire.com/news/home/20260706876183/en/

Action Notes

Vertex Pharmaceuticals Incorporated and Crinetics Pharmaceuticals, Inc a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026.